title: Further insights on the inhibition of HIV type 1 infection in vitro by CD4-modified synthetic peptides containing phenylalanine.
abstract: Phenylalanine-containing peptides from CD4 were synthesized on the basis of chemical similarity with active CD4(81-92)-benzylated peptides. Systematic replacement of amino acids of these peptides bearing the benzyl group by phenylalanine, afforded several peptides that were able to block the binding of gp120 to CD4 and to inhibit HIV-induced syncytium formation. These experiments showed that substitution of residues 81 and 85 by phenylalanine was the most important for activity. Following optimization of the length of phenylalanine-substituted peptides it was found that FYICFVED and FYICFVEDE were the most active. Their IC50 for the inhibition of syncytium formation was around 1.2-1.6 microM. This activity is at least 30 times higher than that of the parent peptide FYIFFVEDQKEEDD previously reported (Lasarte et al., J Acquir Immune Defic Syndr 1994;7:129-134). Binding competition experiments with two different anti-peptide antisera recognizing the V3 region of gp120 and FYICFVEDE, show that the active peptides bind to V3 or to a sterically near region of V3. None of the active peptides was toxic to cells in vitro. The enhanced activity and simplicity of these new phenylalanine-substituted CD4 peptides might be a good starting point for the development of mimotopes of potential use for the treatment of AIDS.
authors.affiliation: Departamento de Medicina Interna, Facultad de Medicina, Universidad de Navarra, Pamplona, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Prieto
authors.forename: J J
authors.initials: JJ
authors.lastname: Lasarte
authors.forename: P
authors.initials: P
authors.lastname: Sarobe
authors.forename: J
authors.initials: J
authors.lastname: Golvano
authors.forename: M P
authors.initials: MP
authors.lastname: Civeira
authors.forename: A
authors.initials: A
authors.lastname: Gullón
authors.forename: J
authors.initials: J
authors.lastname: Prieto
authors.forename: F
authors.initials: F
authors.lastname: Borrás-Cuesta
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology*; D015704:CD4 Antigens / Q000737:chemistry / Q000494:pharmacology*; D002459:Cell Fusion / Q000187:drug effects; D002460:Cell Line; D004797:Enzyme-Linked Immunosorbent Assay; D015726:Giant Cells / Q000821:virology; D015497:HIV-1 / Q000472:pathogenicity*; D006801:Humans; D066298:In Vitro Techniques; D009842:Oligopeptides / Q000737:chemistry / Q000494:pharmacology*; D010446:Peptide Fragments / Q000737:chemistry / Q000494:pharmacology*; D010649:Phenylalanine; D013329:Structure-Activity Relationship
chemical_list: D000998:Antiviral Agents; D015704:CD4 Antigens; D009842:Oligopeptides; D010446:Peptide Fragments; C086848:CD4 (81-92); D010649:Phenylalanine